Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts
Last Updated: Tuesday, March 17, 2020
Among patients with myelofibrosis (MF), ruxolitinib demonstrated clinical meaningful reductions in spleen volume and symptoms, including those with low platelet counts, as well as improvements in symptoms among patients without splenomegaly, according to results from the largest analysis of ruxolitinib and MF to date.
Advertisement
News & Literature Highlights
